Business
Enhanced Genomics Appoints Dr Katerina Leftheris to Its Board of Directors
CAMBRIDGE, England, January 09, 2026--Enhanced Genomics (‘Enhanced’ or ‘the Company’), the biotechnology company pioneering 3D multi-omics to rapidly identify high-confidence, genetically validated drug targets for common diseases, today announced Katerina Leftheris, Ph.D. has joined its Board of Directors. Katerina’s appointment as a Director forms part of the Company’s ongoing strategy to expand its internal therapeutics pipeline for drug targets identified using its 3D multi-omics platform.
About this update from Bristol-myers Squibb Company
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1060,"height":361,"url":"https://media.zenfs.com/en/business-wire.com/92a18962282835085893daa5bca44252"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/VGk1O.l6P6s7PwfQX6hkIw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMyNztjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/92a18962282835085893daa5bca44252","width":960,"height":327},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/uCg3fuBPJF_XFQWLo2Ew5A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMjA7aD03MjI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/92a18962282835085893daa5bca44252","width":1060,"height":361}},"lazy":false},{"type":"text","content":"Experienced leader in preclinical and clinical drug development will support expansion of Company’s therapeutics pipeline for complex and common genetic diseases","length":161,"tagName":"p","attribs":{}},{"type":"text","content":"CAMBRIDGE, England, January 09, 2026--(BUSINESS WIRE)--Enhanced Genomics (‘Enhanced’ or ‘the Company’), the biotechnology company pioneering 3D multi-omics to rapidly identify high-confidence, genetically validated drug targets for common diseases, today announced Katerina Leftheris, Ph.D. has joined its Board of Directors. Katerina’s appointment as a Director forms part of the Company’s ongoing strategy to expand its internal therapeutics pipeline for drug targets identified using its 3D multi-omics platform.","length":515,"tagName":"p"},{"type":"text","content":"Katerina is an experienced scientific and executive leader, with over 30 years of experience in senior scientific positions in large pharma and biotech companies, including Bristol Myers Squibb (BMS), Celgene (acquired by BMS), and Pliant Therapeutics, during which time she led discovery and development programs to advance 15 compounds into clinical development. Most recently, Katerina was Chief Scientific Officer at a machine learning-based oral macrocycle drug development company, Vilya, and is on the Board of Directors and Scientific Advisory boards for several biotech companies focused on therapeutics development. Katerina was recently elected 2026 Vice Chair for the Medicinal Chemistry (MEDI) Division and member of the Committee on Science for the American Chemical Society. She is also a visiting Professor of...